DK1564293T3 - Nervetrådproteingenekspression og detektion af Alzheimers sygdom - Google Patents

Nervetrådproteingenekspression og detektion af Alzheimers sygdom

Info

Publication number
DK1564293T3
DK1564293T3 DK04076254T DK04076254T DK1564293T3 DK 1564293 T3 DK1564293 T3 DK 1564293T3 DK 04076254 T DK04076254 T DK 04076254T DK 04076254 T DK04076254 T DK 04076254T DK 1564293 T3 DK1564293 T3 DK 1564293T3
Authority
DK
Denmark
Prior art keywords
alzheimer
disease
detection
gene expression
protein gene
Prior art date
Application number
DK04076254T
Other languages
English (en)
Inventor
La Monte Suzanne M De
Jack R Wands
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of DK1564293T3 publication Critical patent/DK1564293T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
DK04076254T 1993-04-20 1994-04-20 Nervetrådproteingenekspression og detektion af Alzheimers sygdom DK1564293T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5055993A 1993-04-20 1993-04-20
PCT/US1994/004321 WO1994023756A1 (en) 1993-04-20 1994-04-20 Neural thread protein gene expression and detection of alzheimer's disease

Publications (1)

Publication Number Publication Date
DK1564293T3 true DK1564293T3 (da) 2009-01-12

Family

ID=21965952

Family Applications (2)

Application Number Title Priority Date Filing Date
DK04076254T DK1564293T3 (da) 1993-04-20 1994-04-20 Nervetrådproteingenekspression og detektion af Alzheimers sygdom
DK94915396T DK0697893T3 (da) 1993-04-20 1994-04-20 Nervetrådproteingenekspression og detektion af Alzheimers sygdom

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94915396T DK0697893T3 (da) 1993-04-20 1994-04-20 Nervetrådproteingenekspression og detektion af Alzheimers sygdom

Country Status (11)

Country Link
EP (2) EP0697893B1 (da)
JP (2) JP3513859B2 (da)
KR (1) KR100392244B1 (da)
AT (2) ATE312348T1 (da)
CA (1) CA2161097A1 (da)
DE (2) DE69435136D1 (da)
DK (2) DK1564293T3 (da)
ES (2) ES2255054T3 (da)
NZ (1) NZ266072A (da)
PT (1) PT1564293E (da)
WO (1) WO1994023756A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5936078A (en) * 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
CN1173896A (zh) * 1995-12-12 1998-02-18 协和发酵工业株式会社 新的dna、新的多肽和新的抗体
US7226730B1 (en) 1997-02-26 2007-06-05 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
KR20000075748A (ko) * 1997-02-26 2000-12-26 마빈 씨. 구트리 알츠하이머 병의 치료 또는 예방에 유효한 약물을 선별하기 위한 유전자 변형동물 및 세포계
CA2323889A1 (en) 1997-03-12 1998-09-17 Robert W. Esmond A method for treating or preventing alzheimer's disease
EP1541166B1 (en) * 2001-05-16 2007-12-19 Nymox Corporation Preventing cell death using segments of neural thread proteins
BR0209630A (pt) * 2001-05-16 2004-03-30 Nymox Corp Método de impedir morte de célula usando segmentos de proteìnas em cadeia neurais
US6770797B2 (en) 2001-06-01 2004-08-03 Rhode Island Hospital Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
EP1714979A3 (en) * 2001-11-16 2007-04-25 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
CN101389760A (zh) 2006-02-28 2009-03-18 尼莫克斯股份有限公司 有效治疗肿瘤或其他需要除去或破坏细胞的病症的肽
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
WO2023217890A1 (en) * 2022-05-10 2023-11-16 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting cfp-elk1 intergene region

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2094733T3 (es) * 1988-12-21 1997-02-01 Gen Hospital Corp Deteccion de enfermedades o disfunciones neurologicas.

Also Published As

Publication number Publication date
JP3513859B2 (ja) 2004-03-31
JP2004097227A (ja) 2004-04-02
AU674581B2 (en) 1997-01-02
EP0697893B1 (en) 2005-12-07
KR100392244B1 (ko) 2003-11-28
PT1564293E (pt) 2008-12-02
ES2312913T3 (es) 2009-03-01
EP1564293B9 (en) 2009-08-19
CA2161097A1 (en) 1994-10-27
WO1994023756A1 (en) 1994-10-27
JPH08509808A (ja) 1996-10-15
AU6666994A (en) 1994-11-08
DE69434844T2 (de) 2006-12-14
NZ266072A (en) 1997-07-27
EP1564293B1 (en) 2008-08-27
EP0697893A1 (en) 1996-02-28
DE69434844D1 (de) 2006-10-19
ES2255054T3 (es) 2006-06-16
DK0697893T3 (da) 2006-02-20
EP0697893A4 (en) 1996-12-18
ATE406444T1 (de) 2008-09-15
EP1564293A1 (en) 2005-08-17
ATE312348T1 (de) 2005-12-15
DE69435136D1 (de) 2008-10-09

Similar Documents

Publication Publication Date Title
DK0697893T3 (da) Nervetrådproteingenekspression og detektion af Alzheimers sygdom
EP0442961A4 (en) Hybrid procoagulant proteins
PT939804E (pt) Neutroquina alfa
ATE365744T1 (de) Nukleinsäuremoleküle, proteine und peptide, die im zusammenhang stehen mit dickdarmzellen und dickdarm-krebszellen
DE69434926D1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
SE8106641L (sv) Hybrida humanleukocytinterferoner
DE69735375D1 (de) Genfamilie von apoptose-verwandten peptiden, dadurch kodierte peptide und verfahren zu deren herstellung
ATE73494T1 (de) Antigene proteine und diese enthaltende impfstoffe zur verhuetung von kokzidiose.
DK0961831T3 (da) Humant alfa-endokin
ATE301716T1 (de) Vmp-ähnliche sequenzen von pathogener borrelia
ATE380867T1 (de) Lactoferrinrezeptorgen von moraxella
DE68928728D1 (de) Diagnose von retinoblastoma
BR9710975A (pt) Genes de proteìna de adesão de superfìcie exposta de 120 kda imunodominante de ehrlichia chaffeensis
EA199700256A1 (ru) Выделенные последовательности днк, кодирующие капсидные белки l1 и l2 папилломавируса человека типа 18, вектор для экспресси последовательностей днк, способ получения вирусоподобных частиц и способ индуцирования иммунного ответа
BR9810118A (pt) Anticorpo monoclonal ou policlonal ou ligando equivalente, uso do mesmo, peptìdeo, oligopeptìdeo, polipeptìdeo ou proteìna, uso dos mesmos, sequência de cdna, rna ou dna genÈmico, clone bacteriofago, plasmìdeo biologicamente funcional ou vetor viral, célula hospedeira, processos para a detecção de um autoanticorpo de ocorrência natural, e, de tratamento
BR9915066A (pt) Processo para identificar proteìnas de expressão traduzidas de uma sequência de nucleotìdeos, proteìna recombinante purificada, sequência de nucleotìdeos, processos de triagem para identificar clones de expressão em uma biblioteca, para triagem de uma biblioteca de sequências de nucleotìdeos, para identificar sequências de genes antigênicos de uma amostra de sequências de nucleotìdeos e para identificar uma sequência de gene antigênica terapêutica, vetor recombinante, célula hospedeira, sequência de aminoácidos, polipeptìdeo isolado e purificado, anticorpo, e, processo para tratar uma infecção
KR860006484A (ko) 단백질 또는 당단백질의 제조방법
AU5315790A (en) Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by p. falciparum at the sporozoite stage and in the hepatocytes
NO962596L (no) Nytt tumorsupressorgen
ATE300554T1 (de) Bindegewebe-wachstumsfaktor 3.
ATE187202T1 (de) Nukleotidsequenzen die fur proteine von cryptosporidium kodieren, polypeptide, welche durch diese sequenzen kodiert werden, und kits fur deren benutzung
DE69734890D1 (de) Rdgb-proteine
ATE414772T1 (de) Das hohe knochenmasse gen auf 11q13.3
Schröder et al. Identification of a novel platelet-derived neutrophil-chemotactic polypeptide with structural homology to platelet-factor 4
DE3876227D1 (de) Malaria-spezifische dna-sequenzen, ihre expressionsprodukte und deren verwendung.